Abstract
Online magnetic resonance-guided radiotherapy (oMRgRT) represents one of the most innovative applications of current image-guided radiation therapy (IGRT). The revolutionary concept of oMRgRT systems is the ability to acquire MR images for adaptive treatment planning and also online imaging during treatment delivery. The daily adaptive planning strategies allow to improve targeting accuracy while avoiding critical structures. This ESTRO-ACROP recommendation aims to provide an overview of available systems and guidance for best practice in the implementation phase of hybrid MR-linac systems. Unlike the implementation of other radiotherapy techniques, oMRgRT adds the MR environment to the daily practice of radiotherapy, which might be a new experience for many centers. New issues and challenges that need to be thoroughly explored before starting clinical treatments will be highlighted.
| Original language | English |
|---|---|
| Pages (from-to) | 146-154 |
| Number of pages | 9 |
| Journal | Radiotherapy and oncology |
| Volume | 159 |
| Early online date | 26 Mar 2021 |
| DOIs | |
| Publication status | Published - 1 Jun 2021 |
Keywords
- Adaptation
- Implementation
- MR-Linac
- MR-guided radiotherapy
- Online adaptive
- Radiotherapy
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Radiotherapy and oncology, Vol. 159, 01.06.2021, p. 146-154.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology
AU - Corradini, Stefanie
AU - Alongi, Filippo
AU - Andratschke, Nicolaus
AU - Azria, David
AU - Bohoudi, Omar
AU - Boldrini, Luca
AU - Bruynzeel, Anna
AU - Hörner-Rieber, Juliane
AU - Jürgenliemk-Schulz, Ina
AU - Lagerwaard, Frank
AU - McNair, Helen
AU - Raaymakers, Bas
AU - Schytte, Tine
AU - Tree, Alison
AU - Valentini, Vincenzo
AU - Wilke, Lotte
AU - Zips, Daniel
AU - Belka, Claus
N1 - Funding Information: CB and SC have received research grants and speaker fees/travel support from Elekta, Viewray and Brainlab. FA is a consultant and has received speaker honoraria from Elekta, Varian and Boston scientific. NA has received funding from Brainlab and ViewRay and speaker fees/travel support from ViewRay. DA has received institutional research funding from ViewRay. OB has received speaker fees from ViewRay. LB has received research grants from Varian and ViewRay and speaker fees/travel support from ViewRay. AB has received speaker fees and travel support from ViewRay inc. Amsterdam UMC has research agreements with ViewRay inc. JHR has received speaker fees and travel reimbursement from ViewRay Inc, as well as travel reimbursement form IntraOP Medical and Elekta Instrument AB outside the submitted work. FL has received speaker fees and travel support from ViewRay inc. Amsterdam UMC has research agreements with ViewRay inc. HMcN is funded by a National Institute for Health Research and Health Education England (HEE/NIHR), Senior Clinical Lecturer award. BR has received research support and/or funding from Elekta, Philips, Modus QA, Sun Nuclear, IBA, PTW, Scandidos and speaker fees from Elekta. AT has received research funding from Elekta, Varian and Accuray, and speaker fees/travel grants from Elekta and Genesis Healthcare. VV has received departmental research grants from Varian Medical Systems, ViewRay Inc., Elekta, Merck-Serono, Roche. DZ receives within the framework of research agreements financial and technical support as well as sponsoring for travels and scientific symposia from Elekta, Philips, Siemens, PTW and Sennewald. Research in MRgRT is funded by the German Research Council (DFG, ZI 736/2-1; PAK997/1). The other authors declare that they have no competing interests. Funding Information: CB and SC have received research grants and speaker fees/travel support from Elekta, Viewray and Brainlab. FA is a consultant and has received speaker honoraria from Elekta, Varian and Boston scientific. NA has received funding from Brainlab and ViewRay and speaker fees/travel support from ViewRay. DA has received institutional research funding from ViewRay. OB has received speaker fees from ViewRay. LB has received research grants from Varian and ViewRay and speaker fees/travel support from ViewRay. AB has received speaker fees and travel support from ViewRay inc. Amsterdam UMC has research agreements with ViewRay inc. JHR has received speaker fees and travel reimbursement from ViewRay Inc, as well as travel reimbursement form IntraOP Medical and Elekta Instrument AB outside the submitted work. FL has received speaker fees and travel support from ViewRay inc. Amsterdam UMC has research agreements with ViewRay inc. HMcN is funded by a National Institute for Health Research and Health Education England (HEE/NIHR), Senior Clinical Lecturer award. BR has received research support and/or funding from Elekta, Philips, Modus QA, Sun Nuclear, IBA, PTW, Scandidos and speaker fees from Elekta. AT has received research funding from Elekta, Varian and Accuray, and speaker fees/travel grants from Elekta and Genesis Healthcare. VV has received departmental research grants from Varian Medical Systems, ViewRay Inc., Elekta, Merck-Serono, Roche. DZ receives within the framework of research agreements financial and technical support as well as sponsoring for travels and scientific symposia from Elekta, Philips, Siemens, PTW and Sennewald. Research in MRgRT is funded by the German Research Council (DFG, ZI 736/2-1; PAK997/1). The other authors declare that they have no competing interests. Funding Information: AT would like to thank the Rosetrees Trust, Cancer Research UK (grant C33589/A28284) and the MRC for their support. This work represents independent research supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Publisher Copyright: © 2021 Elsevier B.V. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/6/1
Y1 - 2021/6/1
N2 - Online magnetic resonance-guided radiotherapy (oMRgRT) represents one of the most innovative applications of current image-guided radiation therapy (IGRT). The revolutionary concept of oMRgRT systems is the ability to acquire MR images for adaptive treatment planning and also online imaging during treatment delivery. The daily adaptive planning strategies allow to improve targeting accuracy while avoiding critical structures. This ESTRO-ACROP recommendation aims to provide an overview of available systems and guidance for best practice in the implementation phase of hybrid MR-linac systems. Unlike the implementation of other radiotherapy techniques, oMRgRT adds the MR environment to the daily practice of radiotherapy, which might be a new experience for many centers. New issues and challenges that need to be thoroughly explored before starting clinical treatments will be highlighted.
AB - Online magnetic resonance-guided radiotherapy (oMRgRT) represents one of the most innovative applications of current image-guided radiation therapy (IGRT). The revolutionary concept of oMRgRT systems is the ability to acquire MR images for adaptive treatment planning and also online imaging during treatment delivery. The daily adaptive planning strategies allow to improve targeting accuracy while avoiding critical structures. This ESTRO-ACROP recommendation aims to provide an overview of available systems and guidance for best practice in the implementation phase of hybrid MR-linac systems. Unlike the implementation of other radiotherapy techniques, oMRgRT adds the MR environment to the daily practice of radiotherapy, which might be a new experience for many centers. New issues and challenges that need to be thoroughly explored before starting clinical treatments will be highlighted.
KW - Adaptation
KW - Implementation
KW - MR-Linac
KW - MR-guided radiotherapy
KW - Online adaptive
KW - Radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=85103938763&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.radonc.2021.03.025
DO - https://doi.org/10.1016/j.radonc.2021.03.025
M3 - Article
C2 - 33775715
SN - 0167-8140
VL - 159
SP - 146
EP - 154
JO - Radiotherapy and oncology
JF - Radiotherapy and oncology
ER -